okyopharma.com - Wutah pendapatan taun lumaku OKYO

Logo grafis okyopharma.com (OKYO)

Stable demand for dry eye therapy guarantees OKYO Pharma Limited (OKYO) long-term rent. The sales dynamics over the last 12 months year-over-year confirm this trend, where 0.00 is recorded as the baseline value. R&D efforts in the US and UK strengthen the company's position, while patent protection and stringent FDA requirements create significant barriers to entry for new market players.

Wutah pendapatan YoY sajrone 12 wulan kepungkur OKYO Pharma Limited (OKYO): kanggo periode 11.02.2024 - 18.11.2026

OKYO Pharma Limited (OKYO) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:
Ringkesan analitik perusahaan:OKYO (OKYO Pharma)
Produk dadi OKYO Pharma Inc

For OKYO Pharma Limited (OKYO), which focuses on dry eye medications, the year-over-year (12-month) relative revenue growth rate serves as an indicator of commercial viability. This metric captures the percentage change in sales volume over a rolling year compared to the same period of the previous cycle. The calculation is based on market consensus, bypassing official reporting delays. For a single-product business, this price action reflects the success of the drug's implementation, while steady growth confirms scaling within the mass market.